Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model

Show full item record



Permalink

http://hdl.handle.net/10138/240224

Citation

Kuryk , L , Moller , A-S W , Garofalo , M , Cerullo , V , Pesonen , S , Alemany , R & Jaderberg , M 2018 , ' Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model ' , Journal of Medical Virology , vol. 90 , no. 10 , pp. 1669-1673 . https://doi.org/10.1002/jmv.25229

Title: Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model
Author: Kuryk, Lukasz; Moller, Anne-Sophie W.; Garofalo, Mariangela; Cerullo, Vincenzo; Pesonen, Sari; Alemany, Ramon; Jaderberg, Magnus
Contributor: University of Helsinki, Faculty of Pharmacy
University of Helsinki, Faculty of Pharmacy
University of Helsinki, Faculty of Pharmacy
Date: 2018-10
Language: eng
Number of pages: 5
Belongs to series: Journal of Medical Virology
ISSN: 0146-6615
URI: http://hdl.handle.net/10138/240224
Abstract: Oncolytic adenoviral immunotherapy activates the innate immune system with subsequent induction of adaptive tumor-specific immune responses to fight cancer. Hence, oncolytic viruses do not only eradicate cancer cells by direct lysis, but also generate antitumor immune response, allowing for long-lasting cancer control and tumor reduction. Their therapeutic effect can be further enhanced by arming the oncolytic adenovirus with costimulatory transgenes and/or coadministration with other antitumor therapies. ONCOS-102 has already been found to be well tolerated and efficacious against some types of treatment-refractory tumors, including mesothelin-positive ovarian cancer (NCT01598129). It induced local and systemic CD8+ T-cell immunity and upregulated programmed death ligand 1. These results strongly advocate the use of ONCOS-102 in combination with other therapeutic strategies in advanced and refractory tumors, especially those expressing the mesothelin antigen. The in vivo work presented herein describes the ability of the oncolytic adenovirus ONCOS-102 to induce mesothelin-specific T-cells after the administration of the virus in bagg albino (BALB/c) mice with mesothelin-positive tumors. We also demonstrate the effectiveness of the interferon-gamma the enzyme-linked immunospot (ELISPOT) assay to detect the induction of T-cells recognizing mesothelin, hexon, and E1A antigens in ONCOS-102treated mesothelioma-bearing BALB/c mice. Thus, the ELISPOT assay could be useful to monitor the progress of therapy with ONCOS-102.
Subject: granulocyte-macrophage colony-stimulating factor (GM-CSF)
mesothelin
mesothelioma
oncolytic adenovirus
ONCOS-102
NEUTRALIZING ANTIBODIES
IMMUNOTHERAPY
CHEMOTHERAPY
IMMUNITY
VACCINE
VIRUSES
1183 Plant biology, microbiology, virology
317 Pharmacy
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Kuryk_L_et_al_2018_Journal_of_Medical_Virology.pdf 695.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record